锅圈（2517.HK）2025 年业绩预告点评 业绩兑现优秀，聚力共进迈步 2026 glmszqdatemark 相对走势 -10% 40% 90% 140% 2025/2 2025/8 2026/1 锅圈 恒生指数 相关研究 [盈利预测与财务指标 Table_Forcast] | 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 6,470 | 7,802 | 9,378 | 11,296 | | 增长率（%） | 6.2 | 20.6 | 20.2 | 20.5 | | 经调整净利润 | 311 | 463 | 589 | 728 | | 增长率（%） | 3.1 | 48.9 | 27.3 | 23.6 | | EPS(基于经调整净利润） | 0.11 | 0.17 | 0.21 | 0.27 | | P/E(基于经调整净利润） | 34 | 22 | 18 | 14 | | P/B | 3.3 | 3.1 | 2.8 | 2.5 | 资料来源：Wind，国联民生证券研究所预测（注：股 ...

资料来源：Wind，国联民生证券研究所预测（注：股价为 2026 年 1 月 30 日收盘价,汇率 1HKD=0.89RMB） | 推荐 | 首次评级 | | --- | --- | | 当前价格： | 4.26 港元 | 锅圈（2517.HK）2025 年业绩预告点评 业绩兑现优秀，聚力共进迈步 2026 glmszqdatemark [盈利预测与财务指标 Table_Forcast] | 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 6,470 | 7,802 | 9,378 | 11,296 | | 增长率（%） | 6.2 | 20.6 | 20.2 | 20.5 | | 经调整净利润 | 311 | 463 | 589 | 728 | | 增长率（%） | 3.1 | 48.9 | 27.3 | 23.6 | | EPS(基于经调整净利润） | 0.11 | 0.17 | 0.21 | 0.27 | | P/E(基于经调整净利润） | 34 | 22 | 18 | 14 | | ...

Investment Rating - The investment rating for the company is set at ★★★☆☆ for basic factors and valuation, ★☆☆☆☆ for performance growth, ★★☆☆☆ for industry representation, ★★★☆☆ for industry prosperity, and ★★★★☆ for market conditions [5]. Core Insights - The company holds a leading market position with a global market share of 20.6% in the heat shrink materials industry, ranking first globally, and a domestic market share of 58.5% in China [2]. - The company has demonstrated significant competitive advantages as one of the largest providers of heat shrink materials and communication cable products, benefiting from the strong expansion of high-speed data communication and power transmission [2]. - The company possesses a broad intellectual property portfolio, including 540 invention patents and 1,490 utility model patents in China, showcasing its strong technical capabilities and industry leadership [3]. Financial Summary - The company's revenue for the fiscal year ending December 31 is projected to grow from 53.37 billion RMB in 2022 to 69.20 billion RMB in 2024, with net profit increasing from 6.60 billion RMB to 9.21 billion RMB during the same period [4]. Market Offering - The company plans to issue 1.40 billion shares, with a maximum fundraising amount of 28.12 billion HKD at an offering price of 20.09 HKD per share [6]. - The subscription period for the shares is from February 5 to February 10, with the listing date set for February 13 [6].

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 22.90 and a fair value of HKD 37.45 [4]. Core Insights - Lingbao Gold has undergone over 20 years of transformation focusing on gold resource development, establishing a structure of five major gold mines and one smelting processing enterprise [10][16]. - The company is expected to enter a cycle of increased reserves and production over the next five years, with strategic plans to enhance its scale and establish itself as a leading gold mining enterprise [10][60]. - The ongoing interest rate reduction cycle is anticipated to support a steady rise in gold prices, which will positively impact the company's performance starting in 2026 [10]. - Earnings forecasts indicate significant growth, with expected EPS of RMB 1.18, 2.57, and 3.03 for the years 2025, 2026, and 2027 respectively, leading to a projected PE valuation of 13 times for 2026 [10]. Summary by Sections Company Overview - Lingbao Gold has developed a resource structure comprising five major gold mines and one smelting enterprise, with a total gold reserve of approximately 131.8 tons as of the end of 2024 [10][21]. - The company aims to solidify its foundation and expand its scale, targeting both domestic and international markets for resource integration [10][60]. Industry Analysis - The report highlights that the gold pricing system is expected to remain favorable, with gold prices projected to rise due to a weakening US dollar and lower real interest rates [10][60]. - The gold sector is anticipated to experience a valuation recovery as companies' performances improve with rising gold prices [10]. Financial Projections and Investment Recommendations - Revenue forecasts for the company show a growth trajectory, with expected revenues of RMB 10.53 billion in 2023, increasing to RMB 21.89 billion by 2027 [3]. - The report suggests that the company's strategic acquisitions and resource expansions will support its growth, leading to a fair value estimate of HKD 37.45 per share [10].

化学制药 | 总股本(百万股) | 2,595.70 | | --- | --- | | 流通股本(百万股) | 2,595.70 | | 市价(港元) | 11.42 | | 市值(百万港元) | 29,642.87 | | 流通市值(百万港元) | 29,642.87 | 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn 执业证书编号：S0740524070001 Email：muys@zts.com.cn | 基本状况 | | --- | | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：祝嘉琦 | | 营业收入（百万元） | | 6,640 | 6,635 | 7,690 | 9,009 | 10,427 | | | | 增长率 yoy% | | 4% | 0% | 16% | 17% | 16% | | ...

可灵 3.0 有望进一步推进技术前沿 买入（维持） 核心观点 快手-W 01024.HK 公司研究 | 动态跟踪 核心观点：1 月初可灵海外出圈后，整个 1 月看收入和 DAU 端都保持相对高位，热度持 续性表现好。目前数据意义在于整体稳在更高水位后，从 1 月初主要在低 ARPU 地区流 量扩圈（如东南亚、中亚等）→高付费能力地区收入震荡爬升，预期后者对可灵 ARR 提升作用更大。此外新一代可灵 3.0 版本内测中，统一架构下工作流衔接性更好，且区 别于竞品的迭代在于原生文本输出，预计进一步推进技术前沿水平。产品层面更侧重于 专业创作各环节提效，若年前能全量使用，有望延续 1 月产品热度，带动需求释放。 盈利预测与投资建议 ⚫ 我们预测公司 25-27 年经调整归母净利润为 204/225/259 亿元。维持此前给予公司 26 年 18xPE 估值，对应合理价值为 4,048 亿 CNY，折合 4,542 亿 HKD（港币兑人 民币汇率 0.891），目标价 104.36 港元/股，维持"买入"评级。 风险提示 宏观消费恢复不及预期，国内商业化效率不及预期，海外业务亏损加大，可 灵技术迭代不及预期 公司主要 ...

证券研究报告 先声药业 (2096 HK) 港股通 SIM0500 获里程碑，年内有望 PoC | 华泰研究 | | 事件点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | | 2026 年 | 2 月 04 日│中国香港 | 生物医药 | 目标价(港币): | 19.82 | 2 月 3 日，公司公告其收到艾伯维就 SIM0500 的 4,000 万美元里程碑付款。 该分子临床开发合作进展积极，我们预计其有望年内读出 I 期临床数据。公 司已达成多项 10 亿美元级 BD 出海，创新研发体系与平台技术能力得到验 证。目前公司已授权产品开发进程稳步推进，先必新舌下片、NMTi 载荷 ADC 平台等有望成为下一轮出海重点，公司全球竞争力有望持续兑现。维持"买 入"。 预计临床 I 期开发顺利，有望年内数据读出 SIM0500 是公司自主开发的 BCMA/GPRC5D/CD3 三抗 TCE，于 2025 年 1 月授权艾伯维，现已获 FDA 的 FTD 认定。目前本品处于中美 I 期临床阶段， 国内剂量爬坡持续推进，美国于 2025 年中完成首例患者给药。本 ...

Investment Rating - The report maintains a positive outlook on Innovent Biologics, indicating an "Outperform" rating for the stock, expecting a relative return exceeding the benchmark index over the next 12-18 months [18]. Core Insights - In FY25, Innovent achieved total product revenue of approximately CNY 11.9 billion, representing a year-on-year increase of 45%, marking the first time the company surpassed the CNY 10 billion milestone [5][6]. - The oncology product portfolio has expanded to 13 products, with core products like Tyvyt® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [6][10]. - The chronic disease segment has seen significant commercialization results, with products such as mazdutide (GLP-1/GCG), tafolecimab (PCSK9), and teprotumumab (IGF-1R) driving revenue growth [7][9]. - In Q4 2025, total product revenue reached approximately CNY 3.3 billion, reflecting a 60% year-on-year increase, with six new drugs included in the National Reimbursement Drug List for 2026 [8][10]. - The company is progressing towards its revenue target of CNY 20 billion by 2027, with ongoing development in oncology, metabolism, autoimmune diseases, and ophthalmology [9]. Summary by Sections Financial Performance - Total product revenue for FY25 was approximately CNY 11.9 billion, a 45% increase year-on-year [5]. - Q4 2025 revenue was approximately CNY 3.3 billion, a 60% increase year-on-year [8]. Product Development - The oncology portfolio has expanded to 13 products, with core products maintaining steady growth [6]. - Significant commercialization in chronic diseases, with key products accelerating market uptake [7]. Market Position - The company is moving closer to its revenue target of CNY 20 billion by 2027, with a rich pipeline in various therapeutic areas [9].

Investment Rating - The report maintains a "Buy" rating for Geely Automobile [3][6] Core Insights - Geely's sales performance in January slightly exceeded industry expectations, with total sales of 270,200 units, a year-on-year increase of 1.3% [9] - The company's export sales saw significant growth, with January exports reaching 60,500 units, a year-on-year increase of 121.2% [9] - The report forecasts net profits for 2025-2027 to be 17.041 billion, 20.604 billion, and 24.318 billion yuan respectively, maintaining a target price of 23.37 HKD [3][5] Financial Summary - Revenue projections for 2023-2027 are as follows: 179.204 billion, 240.194 billion, 319.444 billion, 387.363 billion, and 448.685 billion yuan, with growth rates of 21.1%, 34.0%, 33.0%, 21.3%, and 15.8% respectively [5][10] - Operating profit is expected to grow from 3.806 billion yuan in 2023 to 23.173 billion yuan in 2027, with corresponding growth rates of 4.3%, 100.8%, 110.0%, 22.2%, and 18.1% [5][10] - The gross margin is projected to improve from 15.3% in 2023 to 17.3% in 2027 [10][11] - The report indicates a significant increase in the net profit attributable to the parent company, with a forecast of 5.308 billion yuan in 2023, rising to 24.318 billion yuan by 2027 [5][10]

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 2 月 4 日 腾讯控股 本文内容由 Kylie Kwok (郭凯欣) 提供 中信证券财富管理(香港) 产品及投资方案部 中国互联网行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 3 日发布的题为《Games keep strong momentum》的报告，腾讯预计将继续交出稳健业绩，2025 年第四季度总收入和调整后 Ebit 同比大幅增长。 分析指出，网络游戏有望带来积极惊喜并实现同比增长，得益于常青游戏的稳健表现以及新爆款游戏《三角洲行动》 的推动。尽管宏观环境疲弱，广告业务预计仍将同比增长，主要受广告技术升级和交易增长的支撑。随着毛利率扩张， 利润预计将继续快于收入增长。分析指出，腾讯在 2026 年有望维持双位数的游戏增长和广告增长，并被视为全球拥 有最优 ...